Tokyo, Japan
SEARCH FILTERS
Time filter
Source Type

In order to provide a novel cancer treatment method using a FTDTPI combination drug that exhibits markedly excellent anti-tumor effects with fewer side effects, the present invention provides an anti-tumor agent characterized in that the FTDTPI combination drug and an anti-tumor platinum complex are administered in combination.


Patent
Taiho Pharmaceutical Co | Date: 2017-04-21

Provided is a novel method for treating cancer using an HSP90 inhibitor which exhibits a markedly superior antitumor effect and has a reduced side effect. An antitumor agent is characterized in that an azabicyclo compound of the following Formula (1) or a salt thereof is administered in combination with other antitumor agent(s).


Patent
Taiho Pharmaceutical Co | Date: 2017-04-20

To provide a novel compound having a HER2 inhibitory effect and having a cytostatic effect. It is also intended to provide a medicament useful in the prevention and/or treatment of a disease involving HER2, particularly, cancer, on the basis of the HER2 inhibitory effect. The present invention provides a compound of formula (I) wherein X, Y, Z_(1), Z_(2), Z_(3), Z_(4), W, n, R_(1), R_(2), and R_(3 )have meanings as defined in the present specification, or a salt thereof.


Patent
Taiho Pharmaceutical Co | Date: 2017-02-08

In order to provide a novel cancer treatment method using a FTDTPI combination drug that exhibits markedly excellent anti-tumor effects with fewer side effects, the present invention provides an anti-tumor agent characterized in that the FTDTPI combination drug and a taxane compound are administered in combination.


Patent
Taiho Pharmaceutical Co | Date: 2017-04-05

To provide a compound having an inhibitory activity for an androgen receptor. A tetrahydropyridopyrimidine compound represented by the following general formula (I) or a pharmaceutically acceptable thereof (in the formula, X and R are as defined in the specification).


Patent
Taiho Pharmaceutical Co | Date: 2017-01-11

Provided is a salt having a high selectivity to BTK and is useful as a drug ingredient for a pharmaceutical product. It has been found that fumarate of Compound A is free of a characteristic of channel hydrate and is stable and excellent in absorptive property, compared to Compound A or other salts thereof.


Patent
Taiho Pharmaceutical Co | Date: 2017-01-25

Provided is a preventive and/or therapeutic agent for immune diseases containing a compound having a BTK inhibitory activity or a salt thereof, as an active ingredient. A preventive and/or therapeutic agent of immune diseases, comprising a compound represented by Formula (I), where R_(1) to R_(3), W, X, Y, Z, and n represent those as defined in the specification, or a salt thereof, as an active ingredient.


Patent
Taiho Pharmaceutical Co | Date: 2016-05-16

Problem to Be Solved by the Invention: To providing a method for ameliorating DHIC. Means for Solving the Problem: This invention is directed to a treating method for DHIC, comprising the step of administering a therapeutically effective amount of 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexene-1-one, a salt thereof, or a solvate thereof.


Patent
Taiho Pharmaceutical Co | Date: 2017-02-17

The present invention provides an antitumor effect potentiator for enhancing antitumor activity of an antitumor agent comprising tegafur in a therapeutically effective amount, gimeracil in an amount effective for enhancing an antitumor effect, and oteracil potassium in an amount effective for inhibiting a side effect. The antitumor effect potentiator comprising at least one member selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof. The present invention also provides a method for enhancing an antitumor effect of an antitumor agent comprising the step of administering to a patient the aforementioned antitumor effect potentiator; a method for inhibiting the growth of a tumor comprising the step of administering to a patient the aforementioned antitumor effect potentiator and a method for cancer treatment comprising the step of administering to a patient the aforementioned antitumor agent.


Patent
Taiho Pharmaceutical Co | Date: 2017-01-12

A method for treating rheumatoid arthritis, multiple sclerosis, or a disease involving JAK3, including administering a compound of the formula (I) or a salt thereof to a subject

Loading Taiho Pharmaceutical Co collaborators
Loading Taiho Pharmaceutical Co collaborators